Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sigachi IndustriesBOM:543389 -1.97%75 EBITDA Margin % is 13.64% as of Mar. 2026, which is 37% below its 10-year median of 21.54. GuruFocus rates BOM:543389 with a GF Score™ of 75/100 and a GF Value™ of ₹48.18 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 960 Drug Manufacturers companies, Sigachi Industries ranks worse than 81.67% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sigachi Industries's EBITDA for the
three
months ended in Mar. 2026 was ₹166 Mil. Sigachi Industries's Revenue for the
three
months ended in Mar. 2026 was ₹1,219 Mil. Therefore, Sigachi Industries's EBITDA margin for the quarter that ended in Mar. 2026 was 13.64%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sigachi Industries EBITDA Margin % Related Terms
Sigachi Industries EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sigachi Industries's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sigachi Industries's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sigachi Industries EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sigachi Industries's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sigachi Industries's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sigachi Industries (BOM:543389) has a EBITDA Margin % of 13.64% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sigachi Industries and its competitors. This is 37% below median its historical median of 21.54. According to the industry distribution chart, Sigachi Industries ranks #784 out of 960 companies in the Drug Manufacturers industry, placing it in the top 81.7%.
Is Sigachi Industries' EBITDA Margin % too high?
Sigachi Industries' current EBITDA Margin % of 13.64% is 37% below median its 10-year median of 21.54. The Drug Manufacturers industry median EBITDA Margin % is 12.45. Sigachi Industries' value of 13.64% is 9.6% above this industry median. Based on the distribution chart, Sigachi Industries ranks #784 out of 960 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sigachi Industries has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sigachi Industries' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sigachi Industries ranks #784 out of 960 companies for EBITDA Margin %. This places Sigachi Industries in the lower half of its industry. The industry median EBITDA Margin % is 12.45. Sigachi Industries' value of 13.64% is 9.6% above this benchmark. While the company's 10-year median is 21.54 vs. the industry median of 12.45, Sigachi Industries has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.45, based on 960 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sigachi Industries's current EBITDA Margin % of 13.64% is 9.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sigachi Industries and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sigachi Industries's current EBITDA Margin % is 13.64%, which is 37% below median its own 10-year median of 21.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sigachi Industries stock overvalued right now?
Based on GuruFocus' analysis, Sigachi Industries (BOM:543389) is currently considered Possible Value Trap. The stock's GF Value™ is ₹48.18, compared to a current price of ₹25.42 — trading 47.2% below its estimated fair value. The current EBITDA Margin % is 13.64%, which is 37% below median its 10-year median of 21.54 and 9.6% above the Drug Manufacturers industry median of 12.45. Sigachi Industries' overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sigachi Industries (BOM:543389), the current EBITDA Margin % is 13.64% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sigachi Industries (BOM:543389) Overvalued in 2026?
Based on GuruFocus' analysis, Sigachi Industries stock appears to be undervalued.
The current stock price of ₹25.42 is trading 47.2% below its estimated GF Value™ of ₹48.18.
GuruFocus considers Sigachi Industries to be Possible Value Trap.
Key valuation signals for BOM:543389:
EBITDA Margin %: 13.64% (37% below median its 10-year median of 21.54)
GF Value™: ₹48.18 vs. price of ₹25.42 (47.2% below fair value)
Industry Position: 9.6% above the Drug Manufacturers median (#784 of 960)
No single metric tells the full story. See the BOM:543389 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sigachi Industries Ltd is engaged in the manufacturing of Microcrystalline Cellulose (MCC), which is widely used as an excipient for finished dosages in the pharmaceutical industry. The Company is mainly pursuing only one activity which is manufacturing and selling of MCC. The company manufactures MCC of various grades ranging from 15 microns to 250 microns and the crucial grades of MCC manufactured and marketed by the company are branded as HiCel and AceCel.
75GF Score
Get the complete analysis for BOM:543389
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543389 has been successfully added to your 
